ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

First Evidence: Edoxaban Affects TRAP-dependent Platelet Aggregation

1Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, National Centre of Thrombosis and Hemostasis, Martin University Hospital, Martin, Slovakia, 2Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, National Centre of Thrombosis and Hemostasis, Martin University Hospital, Slovakia, Martin, Slovakia, 3Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin University Hospital, First Department of Internal Medicine, Martin, Slovakia

Abstract Number: PB1483

Meeting: ISTH 2020 Congress

Theme: Platelet Disorders and von Willebrand Disease » Platelet Function Disorders, Acquired

Background: Edoxaban is an oral anticoagulant drug and a direct factor Xa inhibitor, which is used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). It is also labelled for the treatment of deep venous thrombosis and pulmonary embolism following initial parenteral anticoagulation. Edoxaban inhibits free factor Xa without the need of antithrombin. This inhibition of factor Xa in the coagulation cascade leads to decreased thrombin generation, and therefore, a reduction in thrombus formation and progression.

Aims: This prospective study aimed to assess the effects of edoxaban on in vitro platelet aggregation in patients with NVAF.

Methods: The local Ethical Committee of the Jessenius Faculty of Medicine in Martin approved this study (EK 1702/2015). It examined quantification of platelet aggregation assessed by light transmission aggregometry in 20 patients treated with edoxaban. The anti-Xa activity (ng/L) was assessed using edoxaban-calibrated anti-Xa chromogenic assays (BIOPHEN Heparin kit, BIOPHEN Edoxaban Plasma Calibrator, BIOPHEN Edoxaban Plasma Calibrator; Aniara Diagnostica, West Chester, OH).

Results: The thrombin receptor activating peptide (TRAP)-induced platelet aggregation was significantly lower two hours after taking edoxaban compared to baseline value (44.7% ± 32.03% vs. 73.3% ± 25.55%; p< 0.0001). In addition, we also performed 15 subanalysis in order to identify the differences in the outcome of different comorbidities, age, dosage, liver and kidney function tests, and concomitant treatment.

Conclusions: Results of the subgroup analyses were consistent with the findings of the main analysis; there was no apparent heterogeneity across the prespecified subgroups. The TRAP-induced platelet aggregation is reduced in non-valvular AF patients receiving edoxaban.
This work was supported by grants VEGA 1/0187/17 and APVV-17-0054.

To cite this abstract in AMA style:

Vadelova L, Sokol J, Nehaj F, Ivankova J, Mokan M, Plamenova I, Zolkova J, Stasko J. First Evidence: Edoxaban Affects TRAP-dependent Platelet Aggregation [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/first-evidence-edoxaban-affects-trap-dependent-platelet-aggregation/. Accessed December 11, 2023.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/first-evidence-edoxaban-affects-trap-dependent-platelet-aggregation/